Former Onyx CEO Coles resurfaces to fund, lead Yumanity
This article was originally published in Scrip
Tony Coles moved on long ago from proteasome inhibitors for blood cancers after the former Onyx Pharmaceuticals chairman and CEO sold the company to Amgen in October 2013 for $10bn and he's finally revealed where he will focus his attention next: protein misfolding in neurodegenerative diseases.
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.